Yield10 Bioscience Performance
| YTENDelisted Stock | USD 1.90 0.04 2.06% |
The firm maintains a market beta of 0.72, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Yield10 Bioscience's returns are expected to increase less than the market. However, during the bear market, the loss of holding Yield10 Bioscience is expected to be smaller as well. Yield10 Bioscience right now maintains a risk of 0.0%. Please check out Yield10 Bioscience value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Yield10 Bioscience will be following its historical returns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Yield10 Bioscience has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, Yield10 Bioscience is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 2.4 M | |
| Free Cash Flow | -10.1 M |
Yield10 |
Yield10 Bioscience Relative Risk vs. Return Landscape
If you would invest 190.00 in Yield10 Bioscience on September 3, 2024 and sell it today you would earn a total of 0.00 from holding Yield10 Bioscience or generate 0.0% return on investment over 90 days. Yield10 Bioscience is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Yield10, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Yield10 Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Yield10 Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Yield10 Bioscience, and traders can use it to determine the average amount a Yield10 Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| YTEN |
Based on monthly moving average Yield10 Bioscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Yield10 Bioscience by adding Yield10 Bioscience to a well-diversified portfolio.
Yield10 Bioscience Fundamentals Growth
Yield10 Stock prices reflect investors' perceptions of the future prospects and financial health of Yield10 Bioscience, and Yield10 Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Yield10 Stock performance.
| Return On Equity | -15.08 | ||||
| Return On Asset | -1.5 | ||||
| Operating Margin | (240.28) % | ||||
| Current Valuation | 3.96 M | ||||
| Shares Outstanding | 642.54 K | ||||
| Price To Earning | (3.19) X | ||||
| Price To Book | 11.23 X | ||||
| Price To Sales | 79.63 X | ||||
| Revenue | 60 K | ||||
| EBITDA | (14.13 M) | ||||
| Cash And Equivalents | 10.16 M | ||||
| Cash Per Share | 2.07 X | ||||
| Total Debt | 3.18 M | ||||
| Debt To Equity | 0.28 % | ||||
| Book Value Per Share | (4.95) X | ||||
| Cash Flow From Operations | (10.07 M) | ||||
| Earnings Per Share | (43.68) X | ||||
| Total Asset | 3.91 M | ||||
| Retained Earnings | (414.15 M) | ||||
| Current Asset | 15.34 M | ||||
| Current Liabilities | 3.91 M | ||||
About Yield10 Bioscience Performance
By examining Yield10 Bioscience's fundamental ratios, stakeholders can obtain critical insights into Yield10 Bioscience's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Yield10 Bioscience is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. Yield10 Bioscience, Inc. was incorporate in 1992 and is headquartered in Woburn, Massachusetts. Yield10 Bioscience operates under Agricultural Inputs classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.Things to note about Yield10 Bioscience performance evaluation
Checking the ongoing alerts about Yield10 Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Yield10 Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Yield10 Bioscience is not yet fully synchronised with the market data | |
| Yield10 Bioscience may become a speculative penny stock | |
| Yield10 Bioscience has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 60 K. Net Loss for the year was (14.46 M) with loss before overhead, payroll, taxes, and interest of (7.3 M). | |
| Yield10 Bioscience currently holds about 10.16 M in cash with (10.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 13.0% of the company outstanding shares are owned by insiders |
- Analyzing Yield10 Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Yield10 Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Yield10 Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Yield10 Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Yield10 Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Yield10 Bioscience's stock. These opinions can provide insight into Yield10 Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Yield10 Stock
If you are still planning to invest in Yield10 Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Yield10 Bioscience's history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |